{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:39:08Z","timestamp":1792395548711,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3160,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1093\/annonc\/mdq462","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T21:12:29Z","timestamp":1287436349000},"page":"877-883","source":"Crossref","is-referenced-by-count":42,"title":["Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"J.","family":"Dorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gkazepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scorilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Soosaipillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Diamandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kiechle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq462_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-2007-1022886","article-title":"Developments in the therapy of advanced FIGO III ovarian cancer","volume":"53","author":"Kuhn","year":"1993","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1093\/annonc\/mdq462_bb0015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO;2-U","article-title":"Radical surgical procedure improves survival time in patients with recurrent ovarian cancer","volume":"70","author":"Janicke","year":"1992","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdq462_bb0020","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq462_bb0025","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6690278","article-title":"Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIC","volume":"79","author":"Kuhn","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq462_bb0030","first-page":"3948","article-title":"Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2","volume":"55","author":"Schmalfeldt","year":"1995","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0035","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/1078-0432.CCR-06-2482","article-title":"Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients","volume":"13","author":"Dorn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1515\/BC.2006.138","article-title":"Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma","volume":"387","author":"Dorn","year":"2006","journal-title":"Biol Chem"},{"key":"10.1093\/annonc\/mdq462_bb0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1160\/TH03-12-0798","article-title":"Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer","volume":"91","author":"Harbeck","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1093\/annonc\/mdq462_bb0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1657541","article-title":"Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy","volume":"78","author":"Schmitt","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1093\/annonc\/mdq462_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00268-002-4050-8","article-title":"Plasmin\/plasminogen system in colorectal cancer","volume":"26","author":"Berger","year":"2002","journal-title":"World J Surg"},{"key":"10.1093\/annonc\/mdq462_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/bst0300207","article-title":"Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers","volume":"30","author":"Duffy","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"10.1093\/annonc\/mdq462_bb0065","first-page":"4617","article-title":"Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424)","volume":"62","author":"Harbeck","year":"2002","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0070","first-page":"1743","article-title":"Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer","volume":"7","author":"Konecny","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/(SICI)1097-0215(19961220)69:6<475::AID-IJC10>3.0.CO;2-0","article-title":"Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors","volume":"69","author":"van der Burg","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdq462_bb0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/gyno.1994.1313","article-title":"Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy","volume":"55","author":"Kuhn","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq462_bb0085","first-page":"2396","article-title":"Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer","volume":"7","author":"Schmalfeldt","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1541-7786.257.2.5","article-title":"Human tissue kallikreins: physiologic roles and applications in cancer","volume":"2","author":"Borgono","year":"2004","journal-title":"Mol Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0095","doi-asserted-by":"crossref","first-page":"15341","DOI":"10.1021\/bi015775e","article-title":"Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase","volume":"40","author":"Takayama","year":"2001","journal-title":"Biochemistry"},{"key":"10.1093\/annonc\/mdq462_bb0100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1474","article-title":"The emerging roles of human tissue kallikreins in cancer","volume":"4","author":"Borgono","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdq462_bb0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10408360490471931","article-title":"The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers","volume":"41","author":"Clements","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1093\/annonc\/mdq462_bb0110","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1749-6632.1994.tb24787.x","article-title":"Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein","volume":"732","author":"Menashi","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1093\/annonc\/mdq462_bb0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0006-291X(03)01271-3","article-title":"Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors","volume":"307","author":"Magklara","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdq462_bb0120","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1046\/j.1432-1033.2002.02960.x","article-title":"Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology","volume":"269","author":"Cloutier","year":"2002","journal-title":"Eur J Biochem"},{"key":"10.1093\/annonc\/mdq462_bb0125","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1515\/BC.2004.061","article-title":"Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation\/inactivation","volume":"385","author":"Bayes","year":"2004","journal-title":"Biol Chem"},{"key":"10.1093\/annonc\/mdq462_bb0130","first-page":"5933","article-title":"Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells","volume":"61","author":"Kamath","year":"2001","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdq462_bb0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdq462_bb0140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.6004\/jnccn.2008.0059","article-title":"Ovarian cancer biomarkers: current options and future promise","volume":"6","author":"Coticchia","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdq462_bb0145","first-page":"1","article-title":"Biomarker discovery in epithelial ovarian cancer by genomic approaches","volume":"96","author":"Mok","year":"2007","journal-title":"Adv Cancer Res"},{"key":"10.1093\/annonc\/mdq462_bb0150","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1158\/1078-0432.CCR-07-1409","article-title":"A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy","volume":"13","author":"Zheng","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/4\/877\/19446107\/mdq462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:42:06Z","timestamp":1711892526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419385631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0923753419385631"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq462","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}